全球肥胖流行病已成为一个重大的公共卫生问题。世界卫生组织指出2022年全球约有25亿成年人被归类为超重，其中8.9亿人属于肥胖，这相当于43%的成年人超重，16%的成年人患有肥胖症。超重或肥胖的有害影响扩展到各种身体功能，导致许多合并症的发展，如高脂血症、2型糖尿病、高血压和其他疾病。越来越多的证据表明，超重/肥胖的发生和发展与整体代谢的稳态调节密切相关。尤其是微生物代谢物，作为肠道微生物与宿主相互作用的主要途径，对维持机体代谢稳态至关重要。根据现有研究，已确定微生物代谢与肥胖有关，如短链脂肪酸（SCFAs）、三甲胺N-氧化物（TMAO）、胆汁酸、亚油酸和支链脂肪酸（BCFAs）。双歧杆菌常被用作功能性食品和膳食补充剂，通过增强代谢功能有助于预防代谢异常疾病。此外，双歧杆菌是肠道菌群中SCFAs的主要产生菌之一，参与调节能量稳态。作为双歧杆菌的一种，市售的短双歧杆菌BBr60 （Bifidobacterium breve BBr60）具有抗炎和抗氧化的特性。
该研究涉及75名超重或肥胖的年轻人，随机分配到短双歧杆菌BBr60组或安慰剂组。两组均接受饮食指导，服用BBr60（1×1010CFU/天）或安慰剂，疗程12周，对干预前后的身体组成、血糖、血脂、肝肾功能、综合代谢组和肠道稳态进行分析。本研究旨在阐明短双歧杆菌BBr60干预与超重/肥胖相关的代谢紊乱的机制，探索其在临床环境中的潜在应用。
Figure 1. The effect of BBr60 on weight, BMI, and body composition in overweight or obese adult population. (A) The effect of BBr60 on weight. (B) The effect of BBr60 on BMI. (C) The effect of BBr60 on body fat percentage (BFP). (D) The effect of BBr60 on where hearts rot (WHR). ** p< 0.001, *** p< 0.001.
Figure 2. Serum metabolic profile between BBr60-after and BBr60-before groups. (A) The OPLS-DA scores of BBr60 vs. placebo group. (B) The OPLS-DA permutation test in BBr60 vs. placebo group. (C) The PCA scores of BBr60 vs. placebo group. (D) The volcano plot of placebo vs. BBr60 group. Significantly upregulated metabolites are represented by red points, and significantly downregu- lated metabolites and nonsignificant different ones are represented by blue or gray points, respec- tively. (E) KEGG classification plot for BBr60 vs. placebo group. (F) Differential abundance score plot for BBr60 vs. placebo group, *** p< 0.001.
Figure 3. Fecal metabolic profile between BBr60-after and BBr60-before groups. (A) The OPLS-DA scores of BBr60 vs. placebo group. (B) The OPLS-DA permutation test in BBr60 vs. placebo group. (C) The PCA scores of BBr60 vs. placebo group. (D) The volcano plot of placebo vs. BBr60 group. Significantly upregulated metabolites are represented by red points, and significantly downregulated metabolites and nonsignificant different ones are represented by blue or gray points, respectively.
Figure 4. Fecal metabolic pathways between BBr60-after and BBr60-before groups. (A) KEGG clas- sification plot for BBr60-after vs. BBr60-before groups. (B) Differential abundance score plot for BBr60-after vs. BBr60-before groups, ** p< 0.01, *** p< 0.001.
Figure 5. α and β diversity analysis of BBr60-after and BBr60-before group based on ace (A), chao1 (B), goods_coverage (C), observed_otus (D), pielou-e (E), Shannon (F), bray_curtis_distance (G), jaccard_distance (H), unweighted_unifrac_distance (I) weighted_unifrac (J) between BBr60, and placebo groups in the 12th week, * p< 0.05.
Figure 6. Bacterial compositions of BBr60-after and BBr60-before groups. (A) Composition of intestinal microbiota in the three groups at phylum level. (B) Composition of intestinal microbiota in the three groups at genus level. (C) Histogram of linear discriminant analysis (LDA) value distribution of intestinal microflora.
Figure 7. Correlation analysis of vital metabolites, intestinal bacteria, and clinic indexes before and after BBr60 intervention in overweight or obesity. (A) correlation analysis between serum metabolites associated with the top 15 changed metabolic pathways and with the top 30 intestinal bacteria before and after BBr60 intervention in overweight or obesity. The R values are represented by gradient colors, where blue and green cells indicate positive and negative correlations, respectively; * p< 0.05 and ** p< 0.01. (B) Correlation analysis between serum metabolites associated with the top 15 changed metabolic pathways and with the top 30 intestinal bacteria before and after BBr60 intervention in overweight or obesity. The R values are represented by gradient colors, where blue and red cells indicate positive and negative correlations, respectively; * p< 0.05 and ** p< 0.01. (C) Correlation analysis between serum metabolites associated with the top 15 changed metabolic pathways and clinic indexes in overweight or obesity. The R values are represented by gradient colors, where blue and red cells indicate positive and negative correlations, respectively; * p< 0.05 and ** p< 0.01.
https://doi.org/10.3390/ijms252010871
（请点击标题查看）
肉与肉制品 蛋与蛋制品 水产品 奶及奶制品
豆及豆制品 果蔬及果蔬制品 大米及米制品 食用菌
炎症性肠病 糖尿病 肝病 神经疾病
（请点击标题查看）
（请点击学者姓名查看）
在线投稿平台链接：https://www.wjx.top/jq/85151447.aspx
标注‘原创’仅代表原创编译，本平台不主张对原文的版权。本平台转载仅仅是出于学术交流和传播信息的需要，并不意味着代表本平台观点或证实其内容的真实性；转载文章版权归原作者所有，作者如果不希望被转载或有侵权行为，请联系本平台删除。由于编译水平有限，推文或简历有不妥之处，深感抱歉，请联系本平台修改或者删除。
